Evidence map›Paper›PMID 34159058›Full record

ArticleBiotechnology reports (Amsterdam, Netherlands)2021

Generic and specific recurrent neural network models: Applications for large and small scale biopharmaceutical upstream processes.

Jens Smiatek, Christoph Clemens, Liliana Montano Herrera, Sabine Arnold, Bettina Knapp, Beate Presser, Alexander Jung, Thomas Wucherpfennig, Erich Bluhmki

Abstract read
In one paragraph

Article in Biotechnology reports (Amsterdam, Netherlands), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jens SmiatekInstitute for Computational Physics, University of Stuttgart, D-70569 Stuttgart, Germany.
Christoph ClemensBoehringer Ingelheim Pharma GmbH & Co. KG, Focused Factory Drug Substance, D-88397 Biberach (Riss), Germany.
Liliana Montano HerreraBoehringer Ingelheim Pharma GmbH & Co. KG, Bioprocess Development Biologicals, D-88397 Biberach (Riss), Germany.
Sabine ArnoldBoehringer Ingelheim Pharma GmbH & Co. KG, Bioprocess Development Biologicals, D-88397 Biberach (Riss), Germany.
Bettina KnappBoehringer Ingelheim Pharma GmbH & Co. KG, Analytical Development Biologicals, D-88397 Biberach (Riss), Germany.
Beate PresserBoehringer Ingelheim Pharma GmbH & Co. KG, Analytical Development Biologicals, D-88397 Biberach (Riss), Germany.
Alexander JungBoehringer Ingelheim Pharma GmbH & Co. KG, Digitalization Development Biologicals CMC, D-88397 Biberach (Riss), Germany.
Thomas WucherpfennigBoehringer Ingelheim Pharma GmbH & Co. KG, Bioprocess Development Biologicals, D-88397 Biberach (Riss), Germany.
Erich BluhmkiBoehringer Ingelheim Pharma GmbH & Co. KG, Analytical Development Biologicals, D-88397 Biberach (Riss), Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The calculation of temporally varying upstream process outcomes is a challenging task. Over the last years, several parametric, semi-parametric as well as non-parametric approaches were developed to provide reliable estimates for key process parameters. We present generic and product-specific recurrent neural network (RNN) models for the computation and study of growth and metabolite-related upstream process parameters as well as their temporal evolution. Our approach can be used for the control and study of single product-specific large-scale manufacturing runs as well as generic small-scale evaluations for combined processes and products at development stage. The computational results for the product titer as well as various major upstream outcomes in addition to relevant process parameters show a high degree of accuracy when compared to experimental data and, accordingly, a reasonable predictive capability of the RNN models. The calculated values for the root-mean squared errors of prediction are significantly smaller than the experimental standard deviation for the considered process run ensembles, which highlights the broad applicability of our approach. As a specific benefit for platform processes, the generic RNN model is also used to simulate process outcomes for different temperatures in good agreement with experimental results. The high level of accuracy and the straightforward usage of the approach without sophisticated parameterization and recalibration procedures highlight the benefits of the RNN models, which can be regarded as promising alternatives to existing parametric and semi-parametric methods.

Indexed as

37N2546N6062M1092B20Autocorrelation functionsGeneric and specific machine learning modelsPrincipal component analysisRecurrent neural networksSimulation of bioreactor processesTemporal evolutionUpstream processes

Identifiers

PMID34159058
PMCPMC8193373

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.